Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Key Takeaways:

• Viridian Therapeutics announced inducement grants under Nasdaq Listing Rule 5635(c)(4).
• The story was published by Eagletribune on October 2, 2025.
• The announcement originated from Waltham, Mass.
• The article appears under business and top categories.
• Business Wire was listed as the creator.

Overview

Viridian Therapeutics has revealed its authorization of inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). According to details reported by Eagletribune, the announcement hails from Waltham, Mass. on October 2, 2025, emphasizing the company’s alignment with established listing regulations.

Nasdaq Listing Rule 5635(c)(4)

Nasdaq’s Listing Rule 5635(c)(4) specifically addresses the conditions under which companies can issue equity-based inducement grants outside of routine shareholder approval. Viridian Therapeutics referenced this rule in its statement to highlight the compliance measures taken as part of this latest round of grants.

Waltham, Mass. Update

Published on October 2, 2025, at 19:58:59 UTC, and shared through Eagletribune, the announcement underscores Waltham, Mass. as a key location for Viridian Therapeutics’ operations or official communications. Although details beyond the initial reveal remain limited, the timing and place of the press release offer further context to observers and stakeholders.

Statement Source

The story originates from Eagletribune, where it was categorized under business and top. The creator, Business Wire, signaled the formal and factual nature of the announcement, aligning with typical corporate communications in the biotech industry. Despite detailed content being restricted to “paid plans,” the central facts convey the significance of Viridian Therapeutics’ regulatory alignment efforts.